Up to 25% off this spring for our immunoassay, flow cytometry and NanoString services
Signed in as:
filler@godaddy.com
Up to 25% off this spring for our immunoassay, flow cytometry and NanoString services
Signed in as:
filler@godaddy.com
The nCounter technology is highly suitable for a diverse range of discovery and translational research applications, encompassing gene expression profiling, tumor profiling, immuno-oncology profiling, single-cell gene expression analysis, miRNA expression analysis, gene fusion and copy number variation (CNV) analysis, lncRNA expression analysis, and ChIP-String expression analysis.
This versatile platform enables the simultaneous digital detection of RNA, DNA, and protein within a single experiment to provide maximum flexibility in each project.
nCounter assays streamline sample analysis by minimizing experimental variables. As a result of this optimization process, precise and accurate measurements of gene expression can be rapidly acquired for targets of interest.
The analysis of the transcriptome serves as an initial investigative approach in exploratory studies such as drug target discovery or identification of biomarkers for specific diseases. Due to its rapid responsiveness to both external and internal stimuli, the transcriptome holds potential for predicting certain conditions. NanoString technology offers an enzyme-free, cDNA conversion and amplification-free method that requires as little as 25 ng of input material. It is compatible with various sample types including total RNA, plasma, serum, PBMC, FFPE, and cell lysate. Numerous gene expression panels comprising 200-770 genes have been developed across diverse research fields including immunology, oncology, and neurology. Most gene expression panels are available in both human and mouse versions.
NanoString has a distinguished track record in delivering state-of-the-art solutions for gene expression analysis, catering to the demands of RNA expression analysis driven by biology across various disease areas. These comprehensive solutions encompass GEP signatures with demonstrated clinical utility in immuno-oncology, breast cancer, lymphoma, and other related fields.
To learn more about Established and Clinically-Relevant Gene Expression Profiling Signatures, click here.
miRNA expression panels have also been developed for profiling human, mouse and rat miRNAs. PicoImmune offers sample analysis using NanoString miRNA Expression Panels which utilize specific oligos to enhance the detection of small ~22 nucleotide miRNAs. The miRNA assays include a target-specific bridge oligo and miRTag in addition to capture and reporter probes, allowing for extension of the miRNA length with the use of the bridge oligo. The resulting hybridization between the extended miRNA:miRTag molecule and two probes can then be counted as usual.
The human, mouse, and rat miRNA Expression Panels contain 827, 577, and 423 assays respectively; approximately 100 ng of total RNA is required for analysis. Click here for further details on these panels.
With nCounter miRNA Expression Panels, we can:
Aberrations in copy number are implicated in many diseases, from genetic disorders to cancer. FISH has traditionally been used to detect CNVs, but the growing number and importance of CNVs has made higher-plex technologies such as microarrays and NGS more attractive. However, these approaches require cumbersome and time-consuming workflows and a significant amount of expertise. Additionally, most microarrays are not able to resolve CNVs from FFPE samples.
NanoString has assays for Copy Number Variation (CNV) analysis and Gene Fusion Assays which are especially suited for FFPE tissue samples. PicoImmune offers sample analysis using the CNV and Gene Fusion panels from NanoString.
CNV is when a section of the genome is repeated, and where the number of repeats varies within a population. CNV can result in e.g. protein misfolding and inactivity giving rise to disease. NanoString has developed the panel Human Cancer CNV for detection of CNV of 87 genes commonly amplified or deleted in cancer. The input amount for the analysis is 300 ng genomic DNA.
Gene Fusion refers to the fusion of two separate genes by chromosomal rearrangement resulting in one hybrid gene. Gene fusions are often found to be drivers for cancer, and the resulting gene is referred to as an oncogene. The RNA input for Gene Fusion assays is app. 100 ng of total RNA, but up to 300 ng if the RNA source is FFPE tissue.
NanoString nCounter Panel List (pdf)
DownloadNanoString nCounter PlexSet Reagent (pdf)
DownloadNanoString Panel Pro User Guide (pdf)
DownloadGEP, AutoImmune-Profiling (pdf)
DownloadGEP, Hallmarks-of-Cancer (pdf)
DownloadGEP, ImmuneExhaustion (pdf)
DownloadGEP, IO-360 (pdf)
DownloadGEP, Myeloid-Innate-Immunity (pdf)
DownloadGEP, NeuroInflammation (pdf)
DownloadGEP, Stem-Cell-Panel (pdf)
DownloadnCounter PanCancer IO 360 Panel Bulletin (PDF)
DownloadnCounter Tumor Signaling 360 Panel Bulletin (PDF)
DownloadCopyright © 2021 NanoBiotec, LLC (dba PicoImmune) - All Rights Reserved.
info@picoimmune.com
Our scientists at PicoImmune are super excited to help you out with your R&D efforts.